Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5915 EUR | +3.68% | -8.29% | -16.63% |
05-13 | Earnings Flash (CARA) CARA THERAPEUTICS Posts Q1 Revenue $2.1M, vs. Street Est of $1.7M | MT |
05-13 | Cara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 5.91M 5.45M 8.06M | Sales 2025 * | 6.29M 5.8M 8.58M | Capitalization | 35.51M 32.74M 48.38M |
---|---|---|---|---|---|
Net income 2024 * | -68M -62.7M -92.66M | Net income 2025 * | -64M -59.01M -87.21M | EV / Sales 2024 * | 9.64 x |
Net Debt 2024 * | 21.5M 19.82M 29.3M | Net Debt 2025 * | 78.9M 72.75M 108M | EV / Sales 2025 * | 18.2 x |
P/E ratio 2024 * |
-0.56
x | P/E ratio 2025 * |
-0.73
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.58% |
Latest transcript on Cara Therapeutics, Inc.
1 week | -8.29% | ||
1 month | -15.80% | ||
3 months | -24.46% | ||
6 months | -33.91% | ||
Current year | -16.63% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 18-08-05 | |
Ryan Maynard
DFI | Director of Finance/CFO | 54 | 22-09-11 |
Scott Terrillion
CMP | Compliance Officer | 61 | 16-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Vogelbaum
CHM | Chairman | 60 | 10-06-30 |
Jeffrey Ives
BRD | Director/Board Member | 73 | 14-07-15 |
Helen Boudreau
BRD | Director/Board Member | 58 | 23-08-01 |
Date | Price | Change |
---|---|---|
24-05-31 | 0.5915 | +3.68% |
24-05-30 | 0.5705 | -3.96% |
24-05-29 | 0.594 | -4.19% |
24-05-28 | 0.62 | -5.78% |
24-05-27 | 0.658 | +2.02% |
Real-time BOERSE MUENCHEN, May 31, 2024 at 03:43 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |
- Stock Market
- Equities
- CARA Stock
- 69C Stock